Published in Schizophr Res on May 18, 2010
Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology (2013) 0.99
Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed. Neuropsychopharmacology (2015) 0.87
Neurocognitive functioning of individuals with schizophrenia: using and not using drugs. Schizophr Bull (2013) 0.83
Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. Psychiatry Res (2012) 0.80
Correlated covariates in ANCOVA cannot adjust for pre-existing differences between groups. Schizophr Res (2010) 0.79
The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability. Front Psychiatry (2014) 0.77
An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use. Front Psychiatry (2012) 0.77
The neural correlates of mental rotation abilities in cannabis-abusing patients with schizophrenia: an FMRI study. Schizophr Res Treatment (2013) 0.76
Cannabis use and cognitive function in first episode psychosis: differential effect of heavy use. Psychopharmacology (Berl) (2015) 0.76
Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia. Eur Arch Psychiatry Clin Neurosci (2015) 0.75
Comorbid substance use disorders in schizophrenia: a latent class approach. Psychiatry Res (2014) 0.75
BRIEF REPORT: THE IMPACT OF ALCOHOL AND CANNABIS MISUSE ON COGNITION AMONG INDIVIDUALS WITH SCHIZOPHRENIA. Schizophr Res Cogn (2014) 0.75
Cannabis and development of dual diagnoses: A literature review. Am J Drug Alcohol Abuse (2016) 0.75
Cannabis use and cognitive dysfunction. Indian J Psychiatry (2011) 0.75
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet (2007) 11.27
Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA (2002) 6.48
Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry (2004) 5.95
Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet (2004) 3.96
Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet (1987) 3.61
The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol Med (2007) 3.45
Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry (2001) 3.27
Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction (2004) 2.97
Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ (2004) 2.93
Rethinking psychosis: the disadvantages of a dichotomous classification now outweigh the advantages. World Psychiatry (2007) 2.82
Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol (2002) 2.80
Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ (2002) 2.74
Psychiatric comorbidities and schizophrenia. Schizophr Bull (2008) 2.69
Cannabis use and age at onset of schizophrenia. Am J Psychiatry (2004) 2.49
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res (2004) 2.06
Cannabis use predicts future psychotic symptoms, and vice versa. Addiction (2005) 1.89
Cannabis dependence and psychotic symptoms in young people. Psychol Med (2003) 1.80
Substance abuse and the onset of schizophrenia. Biol Psychiatry (1996) 1.55
Neurocognitive and social functioning in schizophrenia. Schizophr Bull (1999) 1.49
Defining a cognitive function decrement in schizophrenia. Biol Psychiatry (2005) 1.47
Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr Res (2007) 1.47
Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry (2006) 1.45
Cannabis use and outcome of recent onset psychosis. Eur Psychiatry (2005) 1.42
Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophr Res (2000) 1.40
IQ and mental disorder in young men. Br J Psychiatry (2005) 1.31
Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull (2009) 1.30
Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res (2001) 1.29
Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci (1999) 1.27
What we know: findings that every theory of schizophrenia should explain. Schizophr Bull (2009) 1.27
Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust N Z J Psychiatry (2000) 1.26
Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Biol Psychiatry (2006) 1.22
Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord (2007) 1.21
Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry (2005) 1.20
Does gender contribute to heterogeneity in criteria for cannabis abuse and dependence? Results from the national epidemiological survey on alcohol and related conditions. Drug Alcohol Depend (2006) 1.19
Effects of chronic marijuana use on human cognition. Psychopharmacology (Berl) (1993) 1.17
Dysbindin genotype and negative symptoms in schizophrenia. Am J Psychiatry (2006) 1.17
Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand (2001) 1.16
Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res (2005) 1.15
Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.11
The genetics of symptom-based phenotypes: toward a molecular classification of schizophrenia. Schizophr Bull (2008) 1.11
Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome. J Clin Exp Neuropsychol (2009) 1.10
Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand (1992) 1.09
Do cognitive impairments recover following cessation of cannabis use? Life Sci (1995) 1.01
Specific cognitive deficits and differential domains of social functioning impairment in schizophrenia. Schizophr Res (2005) 1.00
Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr Res (2003) 0.99
Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. Schizophr Res (2004) 0.97
Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Arch Gen Psychiatry (2008) 0.90
Clinical characteristics of adolescents later hospitalized for schizophrenia. Am J Med Genet (2002) 0.89
Understanding differences in marijuana use among urban Black and suburban White high school students from two U.S. community samples. J Ethn Subst Abuse (2006) 0.88
[Relevance of drug use in clinical manifestations of schizophrenia]. Actas Esp Psiquiatr (2002) 0.87
Defining the schizophrenia spectrum: issues for genetic linkage studies. Schizophr Bull (1991) 0.86
Correlates of substance abuse in adolescents with treatment-refractory schizophrenia and schizoaffective disorder. Schizophr Res (2005) 0.84
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA (2009) 6.91
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry (2007) 3.26
Prefrontal white matter in pathological liars. Br J Psychiatry (2005) 3.22
High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron (2011) 3.08
Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proc Natl Acad Sci U S A (2007) 2.81
Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet (2004) 2.71
The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull (2003) 2.67
Length distributions of identity by descent reveal fine-scale demographic history. Am J Hum Genet (2012) 1.91
The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC). Bipolar Disord (2010) 1.90
Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia. Arch Gen Psychiatry (2006) 1.86
Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology (2007) 1.70
Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry (2007) 1.67
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry (2002) 1.66
Genetic variation in DTNBP1 influences general cognitive ability. Hum Mol Genet (2006) 1.61
Elucidating the relationship between DISC1, NDEL1 and NDE1 and the risk for schizophrenia: evidence of epistasis and competitive binding. Hum Mol Genet (2008) 1.60
Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability. Am J Psychiatry (2010) 1.58
Interaction between FEZ1 and DISC1 in regulation of neuronal development and risk for schizophrenia. Neuron (2011) 1.57
White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. Am J Psychiatry (2005) 1.56
Patterns of stress in schizophrenia. Psychiatry Res (2008) 1.55
Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry (2014) 1.50
A role for white matter abnormalities in the pathophysiology of bipolar disorder. Neurosci Biobehav Rev (2009) 1.49
White matter abnormalities in obsessive-compulsive disorder: a diffusion tensor imaging study. Arch Gen Psychiatry (2005) 1.49
Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr Res (2007) 1.47
Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry (2003) 1.47
Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br J Psychiatry (2009) 1.47
Association of the DTNBP1 locus with schizophrenia in a U.S. population. Am J Hum Genet (2004) 1.45
Risk factors for psychosis: impaired social and role functioning. Schizophr Bull (2011) 1.43
Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol (2006) 1.42
Clinical and cognitive correlates of suicide attempts in bipolar disorder: is suicide predictable? J Clin Psychiatry (2011) 1.42
Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar Disord (2010) 1.41
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry (2006) 1.41
Runs of homozygosity implicate autozygosity as a schizophrenia risk factor. PLoS Genet (2012) 1.40
Gray matter structural alterations in psychotropic drug-naive pediatric obsessive-compulsive disorder: an optimized voxel-based morphometry study. Am J Psychiatry (2008) 1.40
Neurocognition as a stable endophenotype in bipolar disorder and schizophrenia. J Nerv Ment Dis (2006) 1.38
Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res (2010) 1.35
Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry (2004) 1.34
D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry (2010) 1.33
High dose D-serine in the treatment of schizophrenia. Schizophr Res (2010) 1.33
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol (2011) 1.31
Volume reduction in prefrontal gray matter in unsuccessful criminal psychopaths. Biol Psychiatry (2005) 1.28
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology (2007) 1.27
White matter development in adolescence: diffusion tensor imaging and meta-analytic results. Schizophr Bull (2012) 1.25
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol (2012) 1.25
Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder. Nat Commun (2013) 1.25
White matter abnormalities in early-onset schizophrenia: a voxel-based diffusion tensor imaging study. J Am Acad Child Adolesc Psychiatry (2005) 1.23
Sex differences in frontal lobe white matter microstructure: a DTI study. Neuroreport (2003) 1.23
Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Biol Psychiatry (2006) 1.22
Effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacology (2004) 1.21
Antipsychotic drugs and obesity. Trends Mol Med (2010) 1.21
DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biol Psychol (2007) 1.21
A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacology (2010) 1.21
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry (2012) 1.20
DTNBP1 genotype influences cognitive decline in schizophrenia. Schizophr Res (2006) 1.20
DISC1 and neurocognitive function in schizophrenia. Neuroreport (2005) 1.19
Dysbindin genotype and negative symptoms in schizophrenia. Am J Psychiatry (2006) 1.17
Corpus callosum abnormalities in psychopathic antisocial individuals. Arch Gen Psychiatry (2003) 1.16
Abnormal temporal lobe white matter as a biomarker for genetic risk of bipolar disorder. Biol Psychiatry (2012) 1.16
Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry (2010) 1.16
The MATRICS consensus cognitive battery in patients with bipolar I disorder. Neuropsychopharmacology (2011) 1.15
Hippocampal structural asymmetry in unsuccessful psychopaths. Biol Psychiatry (2004) 1.15
COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav Brain Funct (2005) 1.14
Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia. Am J Psychiatry (2003) 1.14
Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology (2011) 1.13
The genetics of symptom-based phenotypes: toward a molecular classification of schizophrenia. Schizophr Bull (2008) 1.11